ArticleGastroenterology report2023

RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer.

Kun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.